top of page

AI-Powered Clinical Trial Assistant

Meld AI harnesses the power of AI to provide CROs and sponsors with real-time insights and much-needed tools to support sites.

At Meld, we're passionate about leveraging AI to help trial sites, CROs, and sponsors accelerate clinical trials, by providing trial sites with tools to increase site efficiency. In turn, providing CRO's and sponsor's real-time clinical trial insights

AI Dashboard
Clinical Trial Questions
userprofile

How Meld Works

Find critical information from multiple study documents quickly and accurately 

Meld's AI technology unlocks the information in trial documentation and allows site users to instantly access answers from the corpus of trial documentation through natural language questions, and facilitate knowledge transfer easily within the team.

Secure + Compliant Platform
soc3
ISO
HIPAA

Our team has worked with the world's largest pharmaceutical companies and Contract Research Organizations (CROs).

Roche logo
pfizer logo
novo nordisk logo
BI logo
JJ Logo
AstraZenca Logo

Our Clients

Why Trial Sites
Choose Meld

"I can finally stop CTRL F’ing around"

"The documents we deal with are hundreds of pages long, this will really help reduce the time taken to find answers and reduce protocol deviations"

Regulatory Manager, US

Why Meld

Meld is the ultimate tool for clinical trial sites, CRO's and Sponsors. 

Digital Work Life

Quick and Easy Setup

Getting started with Meld is a breeze. Our platform is easy to set up and requires no hassle or code.

Our platform is designed to be user-friendly and intuitive, so trial sites can focus on managing trials instead of shifting through documents

Multiple Workspaces

Meld's makes it easy to create and switch between multiple workspaces helping trial sites manage multiple trials easily and effectively

checklist

Manage User Access Between Workspaces

checklist

Cross-trial Search

Financial Chart

Features

Meld offers a wide range of features to help streamline your clinical trial. 

Email

Subscribe to our newsletter to get all the latest updates and news about Meld.

Thanks for Subscribing!

bottom of page